Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages

被引:36
作者
Garcia, JEL
Rodriguez, FM
Lopez, AJ
Salgado, MJG
de Cabo, MRM
Losada, JP
Arellano, JLP
机构
[1] Univ Las Palmas de Gran Canaria, Fac Ciencias Med, Dept Ciencias Clin 1, Las Palmas Gran Canaria 35080, Spain
[2] Univ Salamanca, Fac Med, Dept Med, E-37008 Salamanca, Spain
[3] Hosp Univ Salamanca, Salamanca, Spain
关键词
D O I
10.1016/S0954-6111(98)90002-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclosporin A (CsA) is an immunomodulator drug that has been used in the treatment of several types of advanced pulmonary interstitial disease. This beneficial effect occurs mainly in circumstances in which alveolitis due to CD4 lymphocytes is absent, suggesting that CsA acts on other types of cells. The present study was undertaken to determine the effect of CsA on inflammatory cytokine secretion by human alveolar macrophages (AMs). Human AMs were collected by bronchoalveolar lavage from four control subjects and 13 patients with interstitial lung disease. Purified human AMs were incubated with different concentrations of CsA (200, 20 and 2 ng ml(-1)) in the presence or absence of lipopolysaccharide (LPS). Interleukin-1 beta (IL-1 beta), tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-8 levels were measured in supernatants using specific enzyme-linked immunosorbent assays. II was found that CsA inhibits basal secretion of TNF-alpha and IL-8 at 20 and 200 ng ml(-1). However, none of the different concentrations of CsA modified basal secretion of IL-1 beta nor IL-6. By contrast, a lower concentration of CsA (2 ng ml(-1)) inhibits LPS-stimulated secretion of all inflammatory cytokines. It is concluded that CsA exerts a modest effect on inflammatory cytokine production by human AMs.
引用
收藏
页码:722 / 728
页数:7
相关论文
共 29 条
[1]   ADVANCED CRYPTOGENIC FIBROSING ALVEOLITIS - PRELIMINARY-REPORT ON TREATMENT WITH CYCLOSPORINE-A [J].
ALTON, EWFW ;
JOHNSON, M ;
TURNERWARWICK, M .
RESPIRATORY MEDICINE, 1989, 83 (04) :277-279
[2]  
ANDERSSON J, 1992, IMMUNOLOGY, V75, P136
[3]   MECHANISMS OF INHIBITION BY CYCLOSPORINE-A ON PULMONARY LEUKOCYTE ACCUMULATION [J].
CHAPMAN, I ;
MAZZONI, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (04) :99-101
[4]   CYCLOSPORINE THERAPY FOR AUTOIMMUNE-DISEASE [J].
FATHMAN, CG ;
MYERS, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1693-1695
[5]   EFFICACY OF CYCLOSPORINE-A FOR IDIOPATHIC PULMONARY FIBROSIS [J].
FUKAZAWA, M ;
KAWANO, M ;
HISANO, S ;
UEDA, K ;
MATSUBA, K .
EUROPEAN JOURNAL OF PEDIATRICS, 1990, 149 (06) :441-442
[6]   POTENTIAL THERAPEUTIC INITIATIVES FOR FIBROGENIC LUNG-DISEASES [J].
GOLDSTEIN, RH ;
FINE, A .
CHEST, 1995, 108 (03) :848-855
[7]  
HERZYK DJ, 1992, J IMMUNOL, V149, P3052
[8]  
HESS AD, 1986, CRIT REV IMMUNOL, V6, P123
[9]  
HUNNINGHAKE GW, 1995, AM J RESP CRIT CARE, V151, P915
[10]   EFFICACY OF INHALED CYCLOSPORINE IN LUNG-TRANSPLANT RECIPIENTS WITH REFRACTORY REJECTION - CORRELATION OF INTRAGRAFT CYTOKINE GENE-EXPRESSION WITH PULMONARY-FUNCTION AND HISTOLOGIC CHARACTERISTICS [J].
KEENAN, RJ ;
ZEEVI, A ;
IACONO, AT ;
SPICHTY, KJ ;
CAI, JZJ ;
YOUSEM, SA ;
OHORI, P ;
PARADIS, IL ;
KAWAI, A ;
GRIFFITH, BP .
SURGERY, 1995, 118 (02) :385-391